Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02808819) enrolled 446 people in total — 220 in a group receiving a medicine called benralizumab (referred to here as "Benra") every 4 weeks, and 226 receiving the same medicine every 8 weeks. By the end of the study, 189 and 195 people in each group respectively had completed it, with 31 people in each group not finishing. The trial was focused on measuring changes in blood cell counts — specifically several types of cells found in the blood — to understand how the body's blood profile changed over the course of treatment. The reported data shows the following average changes in blood cell levels (measured in billions of cells per litre of blood) from the start of the study to the end. For white blood cells overall (leukocytes), the count went down by an average of 0.254 in the 4-weekly group and 0.498 in the 8-weekly group. A specific type of white blood cell called neutrophils also decreased, by 0.237 and 0.392 respectively. Lymphocytes (another white blood cell type) decreased by 0.098 and 0.142. Basophils (yet another white blood cell type) showed a small increase of 0.014 and 0.012. Monocytes (a further white blood cell type) increased slightly by 0.055 in both groups. Platelets — the cells involved in clotting — increased by an average of 9.1 in the 4-weekly group and 11.9 in the 8-weekly group. It is important to note that this summary only describes the numbers as recorded — it does not indicate whether these changes are meaningful, expected, or unusual in the context of treatment. No secondary outcome data was included in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Asthma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing and able to give your consent to take part before any study-related procedures begin.
- You must have taken part in a previous related study (D3250C00021) for at least 16 weeks but no more than 40 weeks.
- If you are a woman who could become pregnant, you must agree to use an effective form of birth control during the study and for 16 weeks after your last dose of the study medicine.
- If you are a woman who could become pregnant, you must have a negative pregnancy test before receiving the first dose of the study medicine.
- If you are a man who is sexually active, you must agree to use a double barrier method of contraception (such as a condom with spermicide) from your first dose until 16 weeks after your last dose.
Who may not be able to join:
- You may not be eligible if you have a health condition (such as a heart, liver, kidney, nerve, blood, hormonal, or mental health condition) that is not considered stable and could affect your safety, influence the study results, or prevent you from completing the study.
- You may not be eligible if you were found to have a parasitic worm infection during the previous study that required hospital treatment, was not treated, was only partially treated, or did not respond to standard treatment.
- You may not be eligible if there were any significant changes in your health checks (such as blood tests, heart tracings, or urine tests) during the previous study that could put you at risk, affect the study results, or stop you from completing the study.
- You may not be eligible if you have cancer now, or if cancer developed during the previous study (though certain minor skin cancers that have been fully treated or removed may be exceptions — confirm with trial site).
- You may not be eligible if you have received a live vaccine within 30 days before starting the study, during the study, or within 16 weeks after your last dose of the study medicine.
- You may not be eligible if you have received immunoglobulin or blood products within 30 days before your first study visit.
- You may not be eligible if you are planning to have a major operation at any point during the study.
- You may not be eligible if you have previously taken part in this specific study before.
- You may not be eligible if you are currently taking part in another clinical trial involving a drug or treatment.
- AstraZeneca staff involved in planning or running this study, employees of the study centre, or close family members of people involved in running the study are not eligible to join.
- You may not be eligible if you did not properly follow the rules of the previous related study (confirm with trial site).
- You may not be eligible if you are still experiencing a serious side effect or medical problem from the previous study that has not yet resolved.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Basophils, Full Analysis Set; Change From Baseline in Leukocytes, Full Analysis Set; Change From Baseline in Lymphocytes, Full Analysis Set; Change From Baseline in Neutrophils, Full Analysis Set; Change From Baseline in Monocytes, Full Analysis Set; Change From Baseline in Platelets, Full Analysis Set; Change From Baseline in Hematocrit, Full Analysis Set; Change From Baseline in Erythrocytes, Full Analysis Set; Change From Baseline in Hemoglobin, Full Analysis Set; Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set; Change From Baseline in Aspar...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.